Lee's Pharmaceutical Holdings Limited 0950.HK Stock
Lee's Pharmaceutical Holdings Limited Price Chart
Lee's Pharmaceutical Holdings Limited 0950.HK Financial and Trading Overview
Lee's Pharmaceutical Holdings Limited stock price | 1.16 HKD |
Previous Close | 1.5 HKD |
Open | 1.49 HKD |
Bid | 1.5 HKD x 0 |
Ask | 1.56 HKD x 0 |
Day's Range | 1.44 - 1.58 HKD |
52 Week Range | 1.32 - 2.45 HKD |
Volume | 40.5K HKD |
Avg. Volume | 111.92K HKD |
Market Cap | 918.58M HKD |
Beta (5Y Monthly) | 0.957471 |
PE Ratio (TTM) | 17.333332 |
EPS (TTM) | 0.03 HKD |
Forward Dividend & Yield | 0.02 (1.41%) |
Ex-Dividend Date | May 25, 2023 |
1y Target Est | 2.3 HKD |
0950.HK Valuation Measures
Enterprise Value | 775.86M HKD |
Trailing P/E | 17.333332 |
Forward P/E | 8.210526 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.74490863 |
Price/Book (mrq) | 0.47735617 |
Enterprise Value/Revenue | 0.629 |
Enterprise Value/EBITDA | 3.261 |
Trading Information
Lee's Pharmaceutical Holdings Limited Stock Price History
Beta (5Y Monthly) | 0.957471 |
52-Week Change | -19.35% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.45 HKD |
52 Week Low | 1.32 HKD |
50-Day Moving Average | 1.48 HKD |
200-Day Moving Average | 1.62 HKD |
0950.HK Share Statistics
Avg. Volume (3 month) | 111.92K HKD |
Avg. Daily Volume (10-Days) | 69.25K HKD |
Shares Outstanding | 588.84M |
Float | 254.05M |
Short Ratio | N/A |
% Held by Insiders | 63.61% |
% Held by Institutions | 6.09% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.02 |
Trailing Annual Dividend Yield | 1.33% |
5 Year Average Dividend Yield | 199.00% |
Payout Ratio | 0.4707 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 4.15% |
Operating Margin (ttm) | 10.33% |
Gross Margin | 62.50% |
EBITDA Margin | 19.29% |
Management Effectiveness
Return on Assets (ttm) | 2.48% |
Return on Equity (ttm) | 2.16% |
Income Statement
Revenue (ttm) | 1.23B HKD |
Revenue Per Share (ttm) | 2.09 HKD |
Quarterly Revenue Growth (yoy) | -37.20% |
Gross Profit (ttm) | 770.76M HKD |
EBITDA | 237.9M HKD |
Net Income Avi to Common (ttm) | 51.28M HKD |
Diluted EPS (ttm) | 0.09 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 189.3M HKD |
Total Cash Per Share (mrq) | 0.32 HKD |
Total Debt (mrq) | 163.49M HKD |
Total Debt/Equity (mrq) | 8.87 HKD |
Current Ratio (mrq) | 1.002 |
Book Value Per Share (mrq) | 3.268 |
Cash Flow Statement
Operating Cash Flow (ttm) | 283.63M HKD |
Levered Free Cash Flow (ttm) | 68.9M HKD |
Profile of Lee's Pharmaceutical Holdings Limited
Country | Hong Kong |
State | N/A |
City | Sha Tin |
Address | Building 20E |
ZIP | N/A |
Phone | 852 2314 1282 |
Website | https://www.leespharm.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 1102 |
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Q&A For Lee's Pharmaceutical Holdings Limited Stock
What is a current 0950.HK stock price?
Lee's Pharmaceutical Holdings Limited 0950.HK stock price today per share is 1.16 HKD.
How to purchase Lee's Pharmaceutical Holdings Limited stock?
You can buy 0950.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lee's Pharmaceutical Holdings Limited?
The stock symbol or ticker of Lee's Pharmaceutical Holdings Limited is 0950.HK.
Which industry does the Lee's Pharmaceutical Holdings Limited company belong to?
The Lee's Pharmaceutical Holdings Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Lee's Pharmaceutical Holdings Limited have in circulation?
The max supply of Lee's Pharmaceutical Holdings Limited shares is 588.83M.
What is Lee's Pharmaceutical Holdings Limited Price to Earnings Ratio (PE Ratio)?
Lee's Pharmaceutical Holdings Limited PE Ratio is 38.66666800 now.
What was Lee's Pharmaceutical Holdings Limited earnings per share over the trailing 12 months (TTM)?
Lee's Pharmaceutical Holdings Limited EPS is 0.03 HKD over the trailing 12 months.
Which sector does the Lee's Pharmaceutical Holdings Limited company belong to?
The Lee's Pharmaceutical Holdings Limited sector is Healthcare.